Compare Stocks: ORMP, NGNE, CTMX, and BBOT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$9.08	$8.46	$7.00 ▼ $14.87	$727.98M	0.36	264,140 shs	170,946 shs
CTMX CytomX Therapeutics	$3.28 -0.3%	$3.42	$1.90 ▼ $8.21	$714.71M	2.12	2.33 million shs	2.89 million shs
NGNE Neurogene	$38.63 +1.7%	$35.01	$15.93 ▼ $43.66	$773.02M	1.7	173,229 shs	346,579 shs
ORMP Oramed Pharmaceuticals	$4.81 +0.4%	$4.28	$2.06 ▼ $5.19	$200.08M	1.22	183,208 shs	126,129 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	0.00%	+0.22%	+4.13%	+6.20%	+907,999,900.00%
CTMX CytomX Therapeutics	0.00%	-2.38%	-1.50%	-12.77%	+66.50%
NGNE Neurogene	0.00%	+6.89%	+8.60%	+39.41%	+96.99%
ORMP Oramed Pharmaceuticals	0.00%	+7.37%	+15.63%	+20.55%	+132.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$9.08	$8.46	$7.00 ▼ $14.87	$727.98M	0.36	264,140 shs	170,946 shs
CTMX CytomX Therapeutics	$3.28 -0.3%	$3.42	$1.90 ▼ $8.21	$714.71M	2.12	2.33 million shs	2.89 million shs
NGNE Neurogene	$38.63 +1.7%	$35.01	$15.93 ▼ $43.66	$773.02M	1.7	173,229 shs	346,579 shs
ORMP Oramed Pharmaceuticals	$4.81 +0.4%	$4.28	$2.06 ▼ $5.19	$200.08M	1.22	183,208 shs	126,129 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	0.00%	+0.22%	+4.13%	+6.20%	+907,999,900.00%
CTMX CytomX Therapeutics	0.00%	-2.38%	-1.50%	-12.77%	+66.50%
NGNE Neurogene	0.00%	+6.89%	+8.60%	+39.41%	+96.99%
ORMP Oramed Pharmaceuticals	0.00%	+7.37%	+15.63%	+20.55%	+132.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBOT BridgeBio Oncology Therapeutics	2.75	Moderate Buy	$24.40	168.72% Upside
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	262.80% Upside
NGNE Neurogene	2.83	Moderate Buy	$83.67	116.58% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ORMP, NGNE, CTMX, and BBOT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2026	BBOT BridgeBio Oncology Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$27.00 ➝ $25.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00
8/12/2026	NGNE Neurogene	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$69.00 ➝ $81.00
8/12/2026	NGNE Neurogene	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$180.00 ➝ $166.00
8/12/2026	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$70.00 ➝ $65.00
8/10/2026	CTMX CytomX Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
7/21/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	NGNE Neurogene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	BBOT BridgeBio Oncology Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight
7/8/2026	BBOT BridgeBio Oncology Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$27.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	$4.03 per share	N/A
CTMX CytomX Therapeutics	$76.20M	9.38	N/A	N/A	$1.39 per share	2.36
NGNE Neurogene	$930K	831.17	N/A	N/A	$10.85 per share	3.56
ORMP Oramed Pharmaceuticals	$2M	100.05	$0.09 per share	53.02	$7.63 per share	0.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBOT BridgeBio Oncology Therapeutics	-$134.04M	-$2.76	N/A	N/A	N/A	N/A	-46.90%	-42.17%	N/A
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
NGNE Neurogene	-$90.35M	-$5.03	N/A	N/A	N/A	N/A	-45.10%	-41.00%	N/A
ORMP Oramed Pharmaceuticals	$64.05M	$4.12	1.17	N/A	N/A	N/A	-5.17%	-4.54%	N/A

Latest ORMP, NGNE, CTMX, and BBOT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$705.20	N/A	-$705.20	N/A	N/A
8/11/2026	Q2 2026	NGNE Neurogene	-$1.42	-$1.53	-$0.11	-$1.53	N/A	N/A
8/10/2026	Q2 2026	ORMP Oramed Pharmaceuticals	$0.43	-$0.09	-$0.52	$1.84	N/A	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	$0.25	5.20%	N/A	6.07%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBOT BridgeBio Oncology Therapeutics	N/A	4.69	4.69
CTMX CytomX Therapeutics	N/A	9.36	9.36
NGNE Neurogene	N/A	10.65	10.64
ORMP Oramed Pharmaceuticals	N/A	4.98	4.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBOT BridgeBio Oncology Therapeutics	54.89%
CTMX CytomX Therapeutics	67.77%
NGNE Neurogene	52.37%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
BBOT BridgeBio Oncology Therapeutics	24.40%
CTMX CytomX Therapeutics	3.80%
NGNE Neurogene	11.68%
ORMP Oramed Pharmaceuticals	20.77%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBOT BridgeBio Oncology Therapeutics	N/A	80.17 million	60.61 million	N/A
CTMX CytomX Therapeutics	170	217.90 million	209.62 million	Optionable
NGNE Neurogene	90	20.01 million	17.67 million	Optionable
ORMP Oramed Pharmaceuticals	10	41.60 million	32.96 million	Optionable

ORMP, NGNE, CTMX, and BBOT Headlines

Recent News About These Companies

Wall Street Zen Upgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to "Buy"

August 15, 2026 | americanbankingnews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating

August 15, 2026 | marketbeat.com

Oramed: Q2 Earnings Snapshot

August 11, 2026 | chron.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results

August 10, 2026 | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Above 200 Day Moving Average - What's Next?

August 6, 2026 | marketbeat.com

Oramed Pharmaceuticals (ORMP) Projected to Release Quarterly Earnings on Thursday

August 6, 2026 | marketbeat.com

Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $330,853.60 in Stock

July 3, 2026 | insidertrades.com

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

June 25, 2026 | prnewswire.com

ORMP: View inclusion in Russell indexes as positive that could raise awareness in investment community

June 18, 2026 | msn.com

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

June 17, 2026 | prnewswire.com

ORMP: Strategically acquiring interests in medtech & technology companies

June 8, 2026 | msn.com

Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction

May 22, 2026 | seekingalpha.com

Oramed Pharmaceuticals Inc.

May 18, 2026 | marketwatch.com

Oramed Pharmaceuticals Delays Quarterly SEC Filing

May 15, 2026 | tipranks.com

Oramed Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ORMP

May 15, 2026 | benzinga.com

Oramed Pharmaceuticals Incorporated

April 15, 2026 | edition.cnn.com

Oramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38

March 27, 2026 | msn.com

Oramed: Q4 Earnings Snapshot

March 26, 2026 | stamfordadvocate.comS

Lifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with Oramed

March 26, 2026 | finanznachrichten.de

Lifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to Profitability

March 13, 2026 | quiverquant.comQ

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

March 13, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, NGNE, CTMX, and BBOT Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$9.08 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

CytomX Therapeutics NASDAQ:CTMX

$3.28 -0.01 (-0.30%)

As of 08/21/2026 04:00 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Neurogene NASDAQ:NGNE

$38.63 +0.64 (+1.68%)

As of 08/21/2026 04:00 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Oramed Pharmaceuticals NASDAQ:ORMP

$4.81 +0.02 (+0.42%)

As of 08/21/2026 04:00 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, NGNE, CTMX, and BBOT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, NGNE, CTMX, and BBOT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, NGNE, CTMX, and BBOT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, NGNE, CTMX, and BBOT Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

CytomX Therapeutics NASDAQ:CTMX

Neurogene NASDAQ:NGNE

Oramed Pharmaceuticals NASDAQ:ORMP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, NGNE, CTMX, and BBOT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, NGNE, CTMX, and BBOT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, NGNE, CTMX, and BBOT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, NGNE, CTMX, and BBOT Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

CytomX Therapeutics NASDAQ:CTMX

Neurogene NASDAQ:NGNE

Oramed Pharmaceuticals NASDAQ:ORMP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools